|
1
|
Saidi RF and Hejazi Kenari SK: Liver
transplantation for hepatocellular carcinoma: Past, present and
future. Middle East J Dig Dis. 5:181–192. 2013.PubMed/NCBI
|
|
2
|
Silva MF and Sherman M: Criteria for liver
transplantation for HCC: What should the limits be? J Hepatol.
55:1137–1147. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Decaens T, Roudot-Thoraval F, Badran H,
Wolf P, Durand F, Adam R, Boillot O, Vanlemmens C, Gugenheim J,
Dharancy S, et al: Impact of tumour differentiation to select
patients before liver transplantation for hepatocellular carcinoma.
Liver Int. 31:792–801. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sapisochin G, Goldaracena N, Astete S,
Laurence JM, Davidson D, Rafael E, Castells L, Sandroussi C, Bilbao
I, Dopazo C, et al: Benefit of treating hepatocellular carcinoma
recurrence after liver transplantation and analysis of prognostic
factors for survival in a large Euro-American series. Ann Surg
Oncol. 22:2286–2294. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schlitt HJ, Neipp M, Weimann A, Oldhafer
KJ, Schmoll E, Boeker K, Nashan B, Kubicka S, Maschek H, Tusch G,
et al: Recurrence patterns of hepatocellular and fibrolamellar
carcinoma after liver transplantation. J Clin Oncol. 17:324–331.
1999.PubMed/NCBI
|
|
6
|
Ren X, Yu J, Liu H, Zhang P, An X, Zhang N
and Hao X: Th1 bias in PBMC induced by multicycles of auto-CIKs
infusion in malignant solid tumor patients. Cancer Biother
Radiopharm. 21:22–33. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li H, Wang C, Yu J, Cao S, Wei F, Zhang W,
Han Y and Ren XB: Dendritic cell-activated cytokine-induced killer
cells enhance the anti-tumor effect of chemotherapy on non-small
cell lung cancer in patients after surgery. Cytotherapy.
11:1076–1083. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu L, Zhang W, Qi X, Li H, Yu J, Wei S,
Hao X and Ren X: Randomized study of autologous cytokine-induced
killer cell immunotherapy in metastatic renal carcinoma. Clin
Cancer Res. 18:1751–1759. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li R, Wang C, Liu L, Du C, Cao S, Yu J,
Wang SE, Hao X, Ren X and Li H: Autologous cytokine-induced killer
cell immunotherapy in lung cancer: A phase II clinical study.
Cancer Immunol Immunother. 61:2125–2133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nishimura R, Baker J, Beilhack A, Zeiser
R, Olson JA, Sega EI, Karimi M and Negrin RS: In vivo
trafficking and survival of cytokine-induced killer cells resulting
in minimal GVHD with retention of antitumor activity. Blood.
112:2563–2574. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Linn YC, Lau LC and Hui KM: Generation of
cytokine-induced killer cells from leukaemic samples with in
vitro cytotoxicity against autologous and allogeneic leukaemic
blasts. Br J Haematol. 116:78–86. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takayama T, Sekine T, Makuuchi M, Yamasaki
S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi
Y, et al: Adoptive immunotherapy to lower postsurgical recurrence
rates of hepatocellular carcinoma: A randomised trial. Lancet.
356:802–807. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hui D, Qiang L, Jian W, Ti Z and Da-Lu K:
A randomized, controlled trial of postoperative adjuvant
cytokine-induced killer cells immunotherapy after radical resection
of hepatocellular carcinoma. Dig Liver Dis. 41:36–41. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dollinger MM, Howie SE, Plevris JN, Graham
AM, Hayes PC and Harrison DJ: Intrahepatic proliferation of ‘naive’
and ‘memory’ T cells during liver allograft rejection: Primary
immune response within the allograft. FASEB J. 12:939–947.
1998.PubMed/NCBI
|
|
15
|
Sangiolo D, Mesiano G, Carnevale-Schianca
F, Piacibello W, Aglietta M and Cignetti A: Cytokine induced killer
cells as adoptive immunotherapy strategy to augment graft versus
tumor after hematopoietic cell transplantation. Expert Opin Biol
Ther. 9:831–840. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lowdell MW, Lamb L, Hoyle C, Velardi A and
Prentice HG: Non-MHC-restricted cytotoxic cells: Their roles in the
control and treatment of leukaemias. Br J Haematol. 114:11–24.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kägi D, Ledermann B, Bürki K, Seiler P,
Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM and Hengartner H:
Cytotoxicity mediated by T cells and natural killer cells is
greatly impaired in perforin-deficient mice. Nature. 369:31–37.
1994. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Heusel JW, Wesselschmidt RL, Shresta S,
Russell JH and Ley TJ: Cytotoxic lymphocytes require granzyme B for
the rapid induction of DNA fragmentation and apoptosis in
allogeneic target cells. Cell. 76:977–987. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Dai H, Li H, Lv H, Wang T, Fu X
and Han W: Growth of human colorectal cancer SW1116 cells is
inhibited by cytokine-induced killer cells. Clin Dev Immunol.
2011:6214142010.PubMed/NCBI
|
|
20
|
Wang X, Yu W, Li H, Yu J, Zhang X, Ren X
and Cao S: Can the dual-functional capability of CIK cells be used
to improve antitumor effects? Cell Immunol. 287:18–22. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mehta BA, Schmidt-Wolf IG, Weissman IL and
Negrin RS: Two pathways of exocytosis of cytoplasmic granule
contents and target cell killing by cytokine-induced
CD3+CD56+ killer cells. Blood. 86:3493–3499.
1995.PubMed/NCBI
|
